Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah
Annals of the rheumatic diseases.
2016 Sep ;
75 (9) :
e61.
[epub] 20160719
Language English Country United States Media print-electronic
Document type Letter, Comment
Persistent link
https://www.medvik.cz/link/pmid27435063
PubMed
27435063
DOI
10.1136/annrheumdis-2016-210114
PII: S0003-4967(24)01740-0
Knihovny.cz E-resources
- Keywords
- Disease Activity, Inflammation, Treatment,
- MeSH
- Antirheumatic Agents MeSH
- Biosimilar Pharmaceuticals * MeSH
- Etanercept * MeSH
- Immunoglobulin G MeSH
- Antibodies, Monoclonal MeSH
- Receptors, Tumor Necrosis Factor MeSH
- Publication type
- Letter MeSH
- Comment MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- Biosimilar Pharmaceuticals * MeSH
- Etanercept * MeSH
- Immunoglobulin G MeSH
- Antibodies, Monoclonal MeSH
- Receptors, Tumor Necrosis Factor MeSH
References provided by Crossref.org
Rheumatology (Oxford, England).
2017 Dec 01 ;
56 (12) :
2093-2101.
